Diabetes Obes Metab: The relationship between empagliflozin and uric acid metabolism in diabetic patients

Elevated levels of uric acid (UA) are common in patients with type 2 diabetes (T2D) and can lead to gouty arthritis
.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) can reduce UA levels and may reduce the incidence of gout

diabetes

Recently, a research article was published in Diabetes Obesity & Metabolism, an authoritative journal in the field of metabolic endocrine diseases.
Researchers aimed to evaluate the effects of empagliflozin on UA ​​levels, anti-gout drugs and gout attacks
.

The study included 7,020 T2D patients who were randomly assigned to the empagliflozin (10 or 25 mg) or placebo group
.

The researchers used a mixed linear model to evaluate the effects of empagliflozin and placebo on UA ​​concentrations, and a Cox proportional hazard model to study the composite outcome of anti-gout drugs or gout attacks

Compared with placebo, empagliflozin can reduce serum UA levels: adjusted mean (95% CI) treatment difference at 52 weeks of treatment = -0.
37 (-0.
42, -0.
31) mg/dL; this is at baseline UA≥ It is more obvious in patients with 7.
0mg/dL and <7.
0mg/dL: the adjusted mean (95%CI) treatment difference at week 52 is -0.
56(-0.
68,-0.
43)mg/dL and -0.
30(- 0.
37,-0.
24) mg/dL
.

Among the 6607 patients who did not take anti-gout drugs at baseline, 5.

It can be seen that empagliflozin reduced UA levels and gout attacks or reduced the composite outcome of anti-gout drug prescriptions
.

These clinically significant results expand the utility of empagliflozin as a potential anti-gout treatment for T2D patients

Enpagliflozin reduced UA levels and gout attacks or reduced the composite outcome of anti-gout drug prescriptions
.
These clinically significant results expand the utility of empagliflozin as a potential anti-gout treatment for T2D patients
.
Original source: Empagliflozin URIC acid and Metabolism in Diabetes: A POST-hoc Analysis of Trial OUTCOME The EMPA-REG in this message